FINWIRES · TerminalLIVE
FINWIRES

BOM:524816

4 stories mentioning BOM:524816Updated 38d ago

Every FINWIRES story that references BOM:524816, newest first.

What's the latest news on BOM:524816?

Asia

NATCO Pharma's Attributable Profit Plunges in Fiscal Q1

NATCO Pharma (NSE:NATCOPHARM, BOM:524816) recorded a decline in profit attributable to owners for the first fiscal quarter to 2.07 billion Indian rupees from 4.81 billion rupees a year prior.Earnings per share stood at 11.53 rupees, down from 26.84 rupees previously, according to a Friday Indian bourse filing.Revenue from operations slipped to 7.35 billion rupees from 13.3 billion rupees in the year-ago period.The pharma company declared an interim dividend of 1.50 rupees per equity share, payable starting Aug. 26 to shareholders of record as of Aug. 20.

BOM:524816NSE:NATCOPHARM
Asia

NATCO Pharma Acquires Additional 13% Stake in Adcock Ingram

NATCO Pharma (NSE:NATCOPHARM, BOM:524816) has completed the acquisition of an additional 13.25% stake in South Africa's Adcock Ingram Holdings for about 1.81 billion South African rand.The acquisition, completed through NATCO Pharma South Africa, increases NATCO's holding in Adcock Ingram to 49% from 35.75%, according to a Tuesday Indian bourse filing.Shares of the pharma company fell nearly 1% in recent trade.

BOM:524816NSE:NATCOPHARM
Asia

NATCO Pharma Receives INR2.1 Million GST Tax Demand

NATCO Pharma (NSE:NATCOPHARM, BOM:524816) received a GST demand order of 2.1 million rupees, along with interest of 1.7 million rupees and a 2.1 million Indian rupees penalty, following an audit covering April 2020 to December 2024.The demand relates to an alleged shortfall in the amount reported under the reverse charge mechanism in GSTR-3B, according to a Tuesday stock exchange filing. The company said it is evaluating the order and will take appropriate action, adding that it does not expect any material impact on its financial or operational performance.Shares of the company fell nearly 1% in recent trade.

BOM:524816NSE:NATCOPHARM
Asia

Lupin, Natco Win USFDA Nod for Generic Cancer Drug Eribulin Mesylate

Lupin (NSE:LUPIN, BOM:500257) and its alliance partner Natco Pharma (NSE:NATCOPHARM, BOM:524816) said the US Food and Drug Administration has approved Eribulin Mesylate injection, 1 mg/2 mL, according to a filing.The drug is a generic version of Eisai Inc.'s reference drug Halaven, the filing said. It is used for the treatment of metastatic breast cancer in patients who have received prior chemotherapy and for unresectable or metastatic liposarcoma.Halaven recorded estimated annual US sales of $43.7 million, based on IQVIA MAT April 2026 data, it added.Shares of Natco Pharma fell over 1% in Wednesday's trade.

BOM:500257BOM:524816NSE:LUPINNSE:NATCOPHARM

Track with the FINWIRES app suite

FolioX
FolioX
Track BOM:524816 in your portfolio
WheelAI
WheelAI
Analyze BOM:524816 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on BOM:524816